Secondary mutations as mediators of resistance to targeted therapy in leukemia

Keyphrases

• Point mutation 100%
• Leukemia 100%
• Resistance to Targeted Therapy 100%
• Secondary mutation 100%
• FLT3 Inhibitor 100%
• Acute Myeloid Leukemia 66%
• Chronic Lymphocytic Leukemia 66%
• Small Molecules 66%
• Resistance Mechanisms 66%
• Common Themes 33%
• FMS-like Tyrosine Kinase 3 (FLT3) 33%
• Arsenic Trioxide 33%
• ATP Binding Site 33%
• Response Rate 33%
• Bone Marrow 33%
• Targeted Therapy 33%
• Lymphoma 33%
• Downstream Effects 33%
• Acute Leukemia 33%
• Acquired Resistance 33%
• Pro-survival 33%
• Early Identification 33%
• Small Molecule Inhibitors 33%
• Strategies to Overcome 33%
• Kinase Domain 33%
• Chronic Myeloid Leukemia 33%
• Rationally Designed 33%
• Acute Promyelocytic Leukemia 33%
• Via Resistance 33%
• Ibrutinib 33%
• Activation Loop 33%
• FLT3 mutation 33%
• ABT-199 33%
• Kinase Domain mutations 33%
• Crenolanib 33%
• Tyrosine Kinase Domain mutations 33%
• Bruton Tyrosine Kinase Inhibitor 33%
• BH3 Mimetics 33%

Medicine and Dentistry

• Point Mutation 100%
• Mediator 100%
• Leukemia 100%
• Targeted Therapy 100%
• Acute Myeloid Leukemia 66%
• Phosphotransferase 66%
• Protein Tyrosine Kinase 33%
• Arsenic Trioxide 33%
• B-Cell Chronic Lymphocytic Leukemia 33%
• Adenosine Triphosphate 33%
• Acute Promyelocytic Leukemia 33%
• Acute Leukemia 33%
• Binding Site 33%
• Chronic Leukemia 33%
• Ibrutinib 33%
• Chronic Myelogenous Leukemia 33%
• Venetoclax 33%
• Crenolanib 33%
• Bruton Tyrosine Kinase Inhibitor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 100%
• Phosphotransferase 100%
• Leukemia 100%
• Protein Tyrosine Kinase 50%
• Arsenite 50%
• Chronic Lymphatic Leukemia 50%
• Adenosine Triphosphate 50%
• Binding Site 50%
• Promyelocytic Leukemia 50%
• Chronic Myeloid Leukemia 50%
• Chronic Leukemia 50%
• Acute Leukemia 50%
• Ibrutinib 50%
• Venetoclax 50%
• Crenolanib 50%
• Bruton Tyrosine Kinase Inhibitor 50%